Drug intelligence / Profile preview

fluocinonide

Development stage
Approved
Lead developer
Axplora
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Topical
01

Overview

Fluocinonide is a potent synthetic glucocorticoid corticosteroid used topically as an anti-inflammatory and antipruritic agent for the treatment of various skin disorders such as eczema and psoriasis. It works by binding to the cytosolic glucocorticoid receptor in skin cells; this complex then translocates to the cell nucleus where it modulates gene expression by binding to glucocorticoid response elements (GREs). This leads to increased synthesis of lipocortins (such as annexin-1), which inhibit phospholipase A2 and thereby reduce production of inflammatory mediators like prostaglandins and leukotrienes. The drug also suppresses immune responses locally in the skin. Fluocinonide is classified as a high or super-high potency topical corticosteroid depending on formulation concentration. It was first approved in 1971 for use in adults and children over 12 years old[1][2][4][5].

Brand names
Fluocinonide-EFluovixVanosLidexLicon
Other names
fluocinolide
02

Targets

ANXA1 (Annexin A1)GR (Glucocorticoid receptor)PLA2 (Phospholipase A2 group IID)

Beyond the preview

Go deeper on fluocinonide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluocinonide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call